1 / 1

Label-Free Array Systems Provide Measurements That Are Highly Sensitive

Overexpression of clinical drugs in cells with a high level of sequence specificity. As a proof of principle, the developers of global label-free array systems succeeded in verifying market research conducted on human plasma and blood cells. This achievement paved the way for the development of the first automated, multi-step sequentially mixed system that could identify and measure the level of sequence specific to each sample type

indrayani_p
Télécharger la présentation

Label-Free Array Systems Provide Measurements That Are Highly Sensitive

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Label-Free Array Systems; Reduce Cost and Time for Drug Identification and Validation Label-free array systems include two types of biosensors such as optical and impedance-based biosensors, including techniques such as surface plasmon resonance, bio-layer interferometry, isothermal titration calorimetry, etc. Label-free array systems are widely used in the drug discovery process by biotechnology and pharmaceutical companies. The system works on the principle of optical interferometry, impedance-based assays, and refractive index to identify and validate new molecules as the possible drug candidates. Furthermore, label-free array systems help reduce the cost and time for drug identification and validation process. Overexpression of clinical drugs in cells with a high level of sequence specificity. As a proof of principle, the developers of global label-free array systems succeeded in verifying market research conducted on human plasma and blood cells. This achievement paved the way for the development of the first automated, multi-step sequentially mixed system that could identify and measure the level of sequence specific to each sample type. The growth of the independent analysis and verification of data and its utility for personalized medicine led to an increase in the demand for this technology. The trend of the last decade has been towards customized, tailor-made, and label-free array systems. This trend is led by a combination of factors, most prominent among them being the price factor, improved system integration, and better product quality. The cost advantage is driven by the fact that customized systems have unique components. The same component can be used in several applications, whereas a generic product cannot be used in all the applications. Biotechnology organizations are reaping the benefits of this trend. Around 25% of components used in customized and label-free array systems are from biotechnology industries. Read More: https://bit.ly/2TNJj0r Coherent Market Insights

More Related